Ichnos Sciences SA
Clinical Trials
11
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
A clinical trial for patients with relapsed or refractory multiple myeloma, using an experimental drug called ISB 2001 for the first time in humans
- First Posted Date
- 2025-06-16
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Ichnos Sciences S.A.
- Target Recruit Count
- 40
- Registration Number
- 2023-507071-21-01
- Locations
- 🇫🇷
Centre Hospitalier Universitaire De Poitiers, Poitiers, France
🇫🇷Hopital Saint Antoine, Paris Cedex 12, France
🇫🇷Centre Hospitalier Universitaire De Nantes, Nantes, France
Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- Drug: ISB 1442 SC injection escalating dosesDrug: ISB 1442 SC injection at RP2D
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Ichnos Sciences SA
- Target Recruit Count
- 29
- Registration Number
- NCT05427812
- Locations
- 🇺🇸
University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸The University of Chicago Medical Center (UCMC) Duchossois Center for Advanced Medicine (DCAM), Chicago, Illinois, United States
🇺🇸Barbara Ann Karmanos Cancer Institute - Karmanos Cancer Center - Main Campus, Detroit, Michigan, United States
Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- Ichnos Sciences SA
- Target Recruit Count
- 1
- Registration Number
- NCT03983395
- Locations
- 🇺🇸
Ichnos Investigational Site 1, Gilbert, Arizona, United States
🇺🇸Ichnos Investigational Site 5, Los Angeles, California, United States
🇺🇸Ichnos Investigational Site 4, Louisville, Kentucky, United States
Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis
- Conditions
- Moderate to Severe Atopic Dermatitis
- Interventions
- Drug: ISB 830 - Part 2 Group 5Drug: ISB 830 - Part 1 Group 2Drug: ISB 830 - Part 1 Group 3Drug: Placebo - Part 1 Group 4Drug: ISB 830 - Part 1 Group 1Drug: Placebo - Part 2 Group 6
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- Ichnos Sciences SA
- Target Recruit Count
- 462
- Registration Number
- NCT03568162
- Locations
- 🇺🇸
Ichnos Investigational Site 129, Birmingham, Alabama, United States
🇺🇸Ichnos Investigational Site 120, Clovis, California, United States
🇺🇸Ichnos Investigational Site 105, Rolling Hills Estates, California, United States
Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma
- Conditions
- Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2017-10-13
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Ichnos Sciences SA
- Target Recruit Count
- 81
- Registration Number
- NCT03309111
- Locations
- 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Mayo Clinic Cancer Center (MCCC) - Rochester, Rochester, Minnesota, United States
- Prev
- 1
- 2
- Next